Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)

Completed

Conditions studied: Primary Progressive Multiple Sclerosis

In brief

The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.

Key facts

Study ID

NCT05974839

Run by

State University of New York at Buffalo

People needed

732

Starts

2023-10-01

Expected to finish

2024-02-28

Last updated by the study team

2024-09-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient participating in the ORATORIO study
• MRI scans available at baseline
• Presence of T2-weighted image (WI) (FLAIR, T2/PD), and 2D/3D T1-WI at baseline

You may not qualify if…

• None

Where it is running

• Buffalo Neuroimaging Analysis Center — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.